Apleona Wolfferts Gebäudetechnik is to fit cooling, heating, sanitary and fire safety systems in a new production facility for basic fractionation of blood plasma for the biopharmaceutical company CSL Behring in Marburg. Among other equipment, Apleona will equip the five-storey production building M245 covering over 19,000 square metres with four refrigerators. These refrigerators with an output of 700 kW and 250 kW will ensure constant temperatures of minus 15 and minus 25 degrees Celsius respectively throughout the production process and the subsequent storage of the medicines. The building is currently under construction and is expected to be completed by 2020.
In addition to the refrigeration technology, Apleona will also install two heat exchangers with an output of 2,200 kW in the building’s main delivery centre to cover the heating energy requirements. Owing to the high purity requirements for the materials, all technical equipment will be made from corrosion-resistant substances. Three cooling towers with an output of 1,400 kW each will be installed on the roof of the building for the waste heat resulting from the processes. The installed building technology is expected to be ready for use in spring 2019.
CSL Behring, which forms part of the CSL Group, is a world-leading special biotherapeutics company with more than 16,000 employees. In basic fractionation at the Marburg location, the first basic physical biochemical processes are performed, using frozen human plasma as the basis for manufacturing life-saving and life-preserving medicines by means of further complex production steps. These medicines are used worldwide to treat patients with serious, rare and usually hereditary illnesses such as severe coagulation disorders or immune system deficiencies. CSL Behring’s medicines also help save lives in intensive care and emergency medicine.